Changes inTrypanosoma cruzi–Specific Immune Responses after Treatment: Surrogate Markers of Treatment Efficacy | Zendy

Susana A. Laucella | Zendy; Damián PérezMazliah | Zendy; Graciela Bertocchi | Zendy; M Alvarez | Zendy; Gretchen Cooley | Zendy; Rodolfo Viotti | Zendy; María C. Albareda | Zendy; Bruno Lococo | Zendy; Miriam Postan | Zendy; Alejandro Armenti | Zendy; Rick L. Tarleton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Changes inTrypanosoma cruzi–Specific Immune Responses after Treatment: Surrogate Markers of Treatment Efficacy

Author(s) -

Susana A. Laucella,

Damián PérezMazliah,

Graciela Bertocchi,

M Alvarez,

Gretchen Cooley,

Rodolfo Viotti,

María C. Albareda,

Bruno Lococo,

Miriam Postan,

Alejandro Armenti,

Rick L. Tarleton

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/648072

Subject(s) - trypanosoma cruzi , medicine , surrogate endpoint , immunology , chagas disease , immune system , intensive care medicine , latin americans , immune status , virology , parasite hosting , world wide web , computer science , linguistics , philosophy

As many as 20 million people are living with Trypanosoma cruzi infection in Latin American, yet few receive any treatment. The major limitation in developing and evaluating potential new drugs for their efficacy is the lack of reliable tests to assess parasite burden and elimination.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research